Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.99 CHF
−15.76 M CHF
8.80 M CHF
17.24 M
About NEWRON PHARMA N
Sector
CEO
Stefan Weber
Headquarters
Bresso
Website
Founded
2002
ISIN
IT0004147952
FIGI
BBG000QXX5D6
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NWRN is 8.05 CHF — it has decreased by −0.74% in the past 24 hours. Watch NEWRON PHARMA N stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange NEWRON PHARMA N stocks are traded under the ticker NWRN.
NWRN stock has fallen by −5.29% compared to the previous week, the month change is a 15.00% rise, over the last year NEWRON PHARMA N has showed a 75.00% increase.
We've gathered analysts' opinions on NEWRON PHARMA N future price: according to them, NWRN price has a max estimate of 13.65 CHF and a min estimate of 13.65 CHF. Watch NWRN chart and read a more detailed NEWRON PHARMA N stock forecast: see what analysts think of NEWRON PHARMA N and suggest that you do with its stocks.
NWRN reached its all-time high on Jul 6, 2007 with the price of 80.25 CHF, and its all-time low was 0.90 CHF and was reached on May 4, 2020. View more price dynamics on NWRN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NWRN stock is 5.52% volatile and has beta coefficient of 1.47. Track NEWRON PHARMA N stock price on the chart and check out the list of the most volatile stocks — is NEWRON PHARMA N there?
Today NEWRON PHARMA N has the market capitalization of 156.64 M, it has increased by 6.22% over the last week.
Yes, you can track NEWRON PHARMA N financials in yearly and quarterly reports right on TradingView.
NEWRON PHARMA N is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
NWRN net income for the last half-year is −9.19 M CHF, while the previous report showed −8.88 M CHF of net income which accounts for −3.48% change. Track more NEWRON PHARMA N financial stats to get the full picture.
No, NWRN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NEWRON PHARMA N EBITDA is −14.21 M CHF, and current EBITDA margin is −126.18%. See more stats in NEWRON PHARMA N financial statements.
Like other stocks, NWRN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEWRON PHARMA N stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NEWRON PHARMA N technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NEWRON PHARMA N stock shows the buy signal. See more of NEWRON PHARMA N technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.